Ahonen A, Kairemo K, Karnani P, Heikkilä J, Nurmi M, Teräs M, Lukkarinen O
Department of Nuclear Medicine, Turku University Central Hospital, Finland.
Acta Oncol. 1993;32(7-8):723-7. doi: 10.3109/02841869309096127.
Purified human prostate acid phosphatase (PAP) was used to generate a specific monoclonal antibody (FC 3001) for detection of PAP expressed by some prostatic carcinomas. DTPA derivatives of MoAb-F(ab')2-fragments were labeled with indium-111 chloride. This labeled antibody was tested in 15 prostate cancer patients who underwent staging pelvic lymphadenectomy; 9 of them received labeled antibody alone whereas 6 received simultaneous injections of labeled and unlabeled antibody with two dose levels (40 or 80 mg). Biodistribution data obtained by direct blood measurements and imaging procedures indicated that simultaneous injection of unlabeled antibody reduced both the blood elimination rate and the accumulation in the liver. Accumulation of the radionuclide in pelvic lymph node metastases was observed in some patients but in a couple of patients accumulation was noted also in normal lymph nodes. The method cannot in its present design replace staging pelvic lymphadenectomy and further studies are needed for elaboration of clinically useful radioimmunodetection methods.
纯化的人前列腺酸性磷酸酶（PAP）被用于制备一种特异性单克隆抗体（FC 3001），以检测某些前列腺癌所表达的PAP。单克隆抗体F(ab')2片段的二乙三胺五乙酸（DTPA）衍生物用氯化铟-111进行标记。对15例接受盆腔淋巴结清扫分期的前列腺癌患者进行了这种标记抗体的检测；其中9例仅接受标记抗体，而6例同时注射标记和未标记抗体，有两个剂量水平（40或80毫克）。通过直接血液测量和成像程序获得的生物分布数据表明，同时注射未标记抗体可降低血液清除率和肝脏中的蓄积。在一些患者中观察到放射性核素在盆腔淋巴结转移灶中的蓄积，但在少数患者的正常淋巴结中也发现了蓄积。目前设计的该方法不能替代盆腔淋巴结清扫分期，还需要进一步研究以完善临床上有用的放射免疫检测方法。
